Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 12/20 | 0.51 |
| ▸ | MGAM | O43451 | 10/20 | 0.51 |
| ▸ | AMY1A | P0DUB6 | 10/20 | 0.51 |
| ▸ | SI | P14410 | 10/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 10/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312576 | 0.88 | TDO2 (0.53) | TDO2GAAMGAMAMY1ASI | |
| SCHEMBL2070662 | 0.78 | GAA (0.67) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL1312137 | 0.77 | HSP90AA1 (0.49) | TDO2GAAMGAMAMY1ASI | |
| SCHEMBL20529652 | 0.76 | SLC9A1 (0.58) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL31473638 | 0.76 | SLC9A1 (0.58) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL28047881 | 0.73 | HCAR3 (0.59) | TDO2GAAMGAMAMY1ASI | |
| SCHEMBL31642496 | 0.73 | SLC9A1 (0.60) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL26978926 | 0.73 | KMO (0.42) | TDO2GAAMGAMAMY1ASI | |
| SCHEMBL30699124 | 0.73 | AR (0.40) | TDO2GAAMGAMAMY1ASI | |
| SCHEMBL27038551 | 0.73 | AR (0.40) | TDO2GAAMGAMAMY1ASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387568-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NeuroSearch A/S (DK) | 2011-11-23 | — | — | EP | claimed |
| US-20110275684-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2011-11-10 | — | — | US | claimed |
| US-8040036-B2 | Organic light emitting device and method for manufacturing the same | LG CHEM, LTD. (KR) | 2011-10-18 | — | — | US | claimed |
| WO-2010081898-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-07-22 | — | — | WO | claimed |
| EP-2387568-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NeuroSearch A/S (DK) | 2011-11-23 | — | — | EP | disclosed |
| US-20110275684-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2011-11-10 | — | — | US | disclosed |
| US-8040036-B2 | Organic light emitting device and method for manufacturing the same | LG CHEM, LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| WO-2010081898-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275684-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | GABBR1, ABAT, GABBR2 | TDO2 252/4885GAA 1362/4885MGAM 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.